As of September 30, 2021, there were 110,066 shares available under the 2017 Plan including shares that were forfeited under the prior plans for future issuance.

One-third of the total number of shares subject to each stock option vest ratably on each of the first three anniversaries of the grant date, contingent on continued employment, and subject to accelerated vesting in certain circumstances. There were no NQOs granted during the three months ended September 30, 2021.


Outstanding NQOs:	Number of NQOs	Weighted Average Exercise Price ($)	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value ($ in thousands)
Outstanding at June 30, 2021	513,325	13.06	5.17	706
Granted	—	—	—	—
Exercised	—	—	—	—
Forfeited	(5,320)	15.94	—	—
Expired	(18,627)	21.12	—	—
Outstanding at September 30, 2021	489,378	12.75	5.09	185
Exercisable at September 30, 2021	244,315	13.37	4.96	61

The aggregate intrinsic values outstanding at the end of period in the table above represent the total pretax intrinsic values, based on the Company’s closing stock price of $8.41 at September 30, 2021 and $12.69 at June 30, 2021, representing the last trading day of the respective periods, which would have been received by NQO holders had all award holders exercised their NQOs that were in-the-money as of those dates. NQOs outstanding that are expected to vest are net of estimated forfeitures.

At September 30, 2021 and June 30, 2021, respectively, there was $0.7 million and $0.9 million of unrecognized NQO compensation cost. The unrecognized NQO compensation cost at September 30, 2021 is expected to be recognized over the weighted average period of 1.1 years. Total compensation expense for NQOs was $0.2 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively.


Outstanding PNQs:	Number of PNQs	Weighted Average Exercise Price ($)	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value ($ in thousands)
Outstanding at June 30, 2021	11,750	29.76	0.71	—
Granted	—	—	—	—
Exercised	—	—	—	—
Forfeited	—	—	—	—
Expired	(8,035)	28.88	—	—
Outstanding at September 30, 2021	3,715	31.71	1.80	—
Exercisable at September 30, 2021	3,714	31.72	1.80	—

The aggregate intrinsic values outstanding at the end of each fiscal period in the table above represent the total pretax intrinsic values, based on the Company’s closing stock price of $8.41 at September 30, 2021 and $12.69 at June 30, 2021, representing the last trading day of the respective fiscal periods, which would have been received by PNQ holders had all award holders exercised their PNQs that were in-the-money as of those dates.

At September 30, 2021 and June 30, 2021, there was no unrecognized PNQ compensation cost. There was no compensation expense related to PNQs in the three months ended September 30, 2021 and 2020.


Outstanding and Nonvested Restricted Stock Awards:	Shares Awarded	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2021	681,570	10.47
Granted	275,602	8.96
Vested/Released	(114,237)	12.06
Cancelled/Forfeited	(16,592)	5.93
Outstanding and nonvested at September 30, 2021	826,343	11.14

The total grant-date fair value of restricted stock granted during the three months ended September 30, 2021 was $2.5 million.

At September 30, 2021 and June 30, 2021, there was $4.7 million and $2.8 million, respectively, of unrecognized compensation cost related to restricted stock. The unrecognized compensation cost related to restricted stock at September 30, 2021 is expected to be recognized over the weighted average period of 1.3 years. Total compensation expense for restricted stock was $0.5 million and $0.5 million, respectively, in the three months ended September 30, 2021 and 2020.


Outstanding and Nonvested PBRSUs:	PBRSUs Awarded(1)	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2021	354,466	6.06
Granted(1)	158,659	8.91
Vested/Released	—	—
Cancelled/Forfeited	—	—
Outstanding and nonvested at September 30, 2021	513,125	6.94

(1) The target number of PBRSUs is presented in the table. Under the terms of the awards, the recipient may earn between 0% and 200% of the target number of PBRSUs depending on the extent to which the Company meets or exceeds the achievement of the applicable financial performance goals.

At September 30, 2021 and June 30, 2021, there was $2.3 million and $1.0 million, respectively, of unrecognized PBRSU compensation cost. The unrecognized PBRSU compensation cost at September 30, 2021 is expected to be recognized over the weighted average period of 2.7 years. Total compensation expense for PBRSUs was $106.5 thousand and $49.6 thousand, respectively, for the three months ended September 30, 2021 and 2020.

CSRSUs vest in equal installments over a three-year period from the grant date, and are cash-settled upon vesting based on the Company’s common stock closing share price on the vesting date.

The CSRSUs are accounted for as liability awards, and compensation expense is measured at fair value on the date of grant and recognized on a straight-line basis over the vesting period net of forfeitures. Compensation expense is remeasured at each reporting date with a cumulative adjustment to compensation cost during the period based on changes in the Company’s common stock closing share price.


Outstanding and Nonvested CSRSUs:	CSRSUs Awarded	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2021	185,602	4.31
Granted	85,851	8.91
Vested/Released	—	—
Cancelled/Forfeited	(10,440)	4.31
Outstanding and nonvested at September 30, 2021	261,013	5.82

At September 30, 2021 and June 30, 2021, there was $1.8 million and $2.0 million, respectively, of unrecognized compensation cost related to CSRSU. The unrecognized compensation cost related to CSRSU at September 30, 2021 is expected to be recognized over the weighted average period of 2.5 years. Total compensation expense for CSRSUs was a credit of $5,896 thousand in the three months ended September 30, 2021.

In November 2019, the Company granted PCAs under the 2017 Plan to certain employees. The PCAs cliff vest on the third anniversary of the date of grant based on the Company’s achievement of certain financial performance goals for the performance period July 1, 2019 through June 30, 2022, subject to certain continued employment conditions and subject to acceleration provisions of the 2017 Plan. At the end of the three-year performance period, the amount of PCAs that actually

vest will be 0% to 200% of the target amount, depending on the extent to which the Company meets or exceeds the achievement of those financial performance goals measured over the full three-year performance period.

The PCAs are measured initially based on a fixed amount of the awards at the date of grant and are required to be re-measured based on the probability of achieving the performance conditions at each reporting date until settlement. Compensation expense for PCAs is recognized over the applicable performance periods. The Company records a liability equal to the cost of PCAs for which achievement of the performance condition is deemed probable. As of September 30, 2021, there was no liability and no unrecognized PCA compensation cost since it was deemed not probable that the Company will achieve the target performance conditions.